Table 1.
Patient and treatment characteristics
| Variable | Value |
|---|---|
| Subjects | |
| N | 42 |
| age (years) | 56.8±15.5 |
| sex (male/female) | 25/17 |
| weight (kg) | 95.1±26.8 |
| AKI | 36/42 |
| 24-hour urine output (ml) | 38 (157) |
| CCF score (n=36) | 7.9±2.8 |
| survival (%) | 50.0 |
| center (CCF/UAB) | 19/23 |
| Treatment | |
| CRRT mode (CVVHD/CVVHDF) | 19/23 |
| CRRT dose (ml/kg per hour) | 25.7 (15.8) |
| CRRT machine (Prismaflex/NxStage) | 34/8 |
| piperacillin dose (2 g/3 g) | 19/23 |
| piperacillin dosing interval (6 h/8 h/12 h) | 23/16/3 |
| cumulative 24-hour piperacillin dose (g) | 8.6±1.5 |
Data are presented as mean ± SD or median (intraquartile range). CCF, Cleveland Clinic, Cleveland, Ohio; UAB, University of Alabama, Birmingham, Alabama; CRRT, continuous renal replacement therapy; CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous venovenous hemodiafiltration.